Health Canada recently published two guidance documents, effective May 23, 2018, that address the reporting of adverse reactions to marketed health products (excluding blood and blood components and cells, tissues and organs). First, Reporting Adverse Reactions to Marketed Health Products provides assistance on reporting adverse reactions to marketed health products including good case management practices. Second, Preparing and Submitting Summary Reports for Marketed Drugs and Natural Health Products addresses the format and content of annual summary reports (ASRs) and issue-related summary reports (IRSRs), as well as procedures for submission of these reports to Health Canada.
Related Publications & Articles
-
CADTH announces the launch of Post-Market Drug Evaluation Program
On September 1, 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of its Post-Market Drug Evaluation Program.Read More -
Health Canada releases new guidance document on clinical evidence requirements for medical devices
On November 15, 2022, Health Canada released a new guidance document, “ Guidance on clinical evidence requirements for medical devices.” In it, Health Canada provides guidance on clinical evidence req...Read More -
Federal Court of Appeal restores Minister of Health’s decision to grant RUZURGI NOC despite FIRDAPSE data protection
The Federal Court found that subsection C.08.004.1(3) of the Food and Drug Regulations applied to prevent the Minister from issuing an NOC in view of the data protection granted to FIRDAPSE, a drug co...Read More